Navigation Links
IRIDEX Reports Record 2012 Fourth Quarter Results

MOUNTAIN VIEW, Calif., Feb. 28, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 29, 2012.  

  • Ophthalmology revenues in the fourth quarter were $9.2 million, compared to $8.6 million in the prior year period and $7.9 million in the 2012 third quarter. The fourth quarter results were a record high for ophthalmology sales in a quarter.
  • Gross margin for the fourth quarter was 47.0%, compared to 49.6% in both the prior year period and the 2012 third quarter. Margins were impacted in the quarter by a shift in product mix towards the sale of laser systems – including a greater-than-expected response to promotional pricing during a key trade show during the period.
  • Operating expenses were $4.0 million in the fourth quarter compared to $3.1 million in the prior year period, which included a one-time credit for a legal settlement of $1.3 million; and $4.5 million in the 2012 third quarter, which included one-time severance expenses of approximately $0.7 million.
  • Income from continuing operations for the fourth quarter was $0.3 million or $0.03 per diluted share, compared with income from continuing operations of $0.8 million, or $0.08 per diluted share, in the prior year period.  
  • Guidance for first quarter 2013: The Company expects to achieve revenues between $8.7 million and $9.0 million and gross margins between 47% and 49%.
    Operating expenses are expected to be between $3.8 million and $4.0 million. Additionally, the Company received $0.5 million in the form of a cash distribution from an insurance carrier which will be recorded in the first quarter.  
  • CEO William M. Moore said, "We have implemented a number of changes to the organization flattening the management structure and making the focus more customer-centric and market driven with an eye to profitability. We are now investing in products that our customers want, that can be delivered to the market in a reasonable amount of time and that are aligned with growing clinical trends in ophthalmology.  And we are making these changes in the framework of fiscal controls and a focus on generating cash and enhancing shareholder value."

    Moore continued, "Going forward, we will look to grow and increase profitability, we will be opportunistic in acquiring or partnering with ophthalmic companies that have developed excellent technologies and we will continue to deploy cash from our strong balance sheet and profitable operations to directly benefit our shareholders through our share buyback program. For the last two years we had committed up to $4.0 million to our stock repurchase program which ended this February. Today, the Board approved a new one year $3.0 million stock repurchase program that replaces our prior two year $4.0 million program."

    The preceding commentary relates to the results of the Company's continuing ophthalmology business. In February 2012, the Company sold its aesthetics laser business and the financial statements reflect the results of its aesthetics laser business as discontinued operations.

    Fourth Quarter Business Highlights

  • The Company completed a tender offer that resulted in the repurchase of an aggregate of 487,500 shares of its common stock at a purchase price of $4.10 per share, for a total cost of approximately $2.0 million.  Those shares represented approximately 5.5 percent of IRIDEX's then issued and outstanding shares of common stock. 
  • The Company announced FDA 510(k) and CE clearance of the TxCell™ Scanning Laser Delivery System.
    This new product saves significant time in a variety of laser photocoagulation procedures by allowing physicians to deliver the laser in a multi-spot scanning mode, a more efficient method for these procedures than the traditional single spot mode.  Management believes that the clinical and practice benefits of this technology will accelerate the adoption of IRIDEX' proprietary MicroPulse™ technology as it applies to several clinical procedures.
  • Conference Call IRIDEX management will conduct a conference call later today, Thursday, February 28, 2013 at 5:00 p.m. Eastern Time.  Interested parties may access the live conference call via telephone by dialing (866) 225-8754 (U.S.) or (480) 629-9818 (International) and quoting Conference ID 4603021, or by visiting the Company's website at A telephone replay will be available beginning on Thursday, February 28, 2013 through Thursday, March 7, 2013 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4603021. In addition, later today an archived version of the webcast will be available on the Company's website at

    About IRIDEX IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at

    Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the size and growth of and trends in the markets in which the Company operates, the success of the Company's development, marketing and sales efforts, MicroPulse laser therapy, the Company's growth strategy, the Company's acquisition strategy, sales revenue growth, operational plans, profitability, the Company's projected fiscal 2013 financial results and the Company's share repurchase program. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2012, June 30, 2012 and September 29, 2012 which were filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


     IRIDEX CorporationCondensed Consolidated Statements of Operations(In thousands, except per share data)(unaudited)Three Months EndedTwelve Months EndedDecember 29,December 31,December 29,December 31,2012201120122011Total revenues

    33,159Cost of revenues

    4,8904,34217,51316,869Gross profit

    4,3384,27816,34616,290Operating expenses:Research and development

    1,0911,1664,3853,913Sales and marketing

    2,0342,1477,8957,458General and administrative

    9081,0664,9264,259Legal settlement, net of expenses

    -(1,274)-(1,274)Total operating expenses

    4,0333,10517,20614,356Income (loss) from operations

    3051,173(860)1,934Legal settlement

    --800800Other expense, net

    (18)(250)(210)(296)Income (loss) from continuing operations before income taxes

    287923(270)2,438Provision for (benefit from) income taxes

    34122(100)297Income (loss) from continuing operations

    253801(170)2,141Income (loss) from discontinued operations, net of tax

    149(15)(264)469(Loss) gain on sale of discontinued operations, net of tax

    (160)-1,872-(Loss) income from discontinued operations, net of tax

    (11)(15)1,608469Net income

    2,610Net (loss) income per share: Basic:  Continuing operations

    $0.03$0.09($0.02)$0.24  Discontinued operations

    ($0.00)($0.00)$0.18$0.05$0.03$0.09$0.16$0.29 Diluted:  Continuing operations

    $0.03$0.08($0.02)$0.21  Discontinued operations

    ($0.01)($0.00)$0.18$0.05$0.02$0.08$0.16$0.26Weighted average shares used in computing net income per share   Basic

    8,8208,9458,9358,958  Diluted


    IRIDEX CorporationCondensed Consolidated Balance Sheets(In thousands)(unaudited)December 29,December 31,20122011AssetsCurrent Assets:Cash and cash equivalents

    ,789Accounts receivable, net

    5,4805,551Inventories, net

    8,0356,659Prepaids and other current assets

    1,129464Current assets of discontinued operations

    5106,043Total current assets

    27,05529,506Property and equipment, net

    483325Other long-term assets

    287199Other intangible assets, net


    533533Non-current assets of discontinued operations

    -841Total assets

    $   28,912$  32,149Liabilities and Stockholders' EquityCurrent Liabilities:Accounts payable

    ,580Accrued compensation

    1,5631,180Accrued expenses

    1,2421,920Accrued warranty

    453556Deferred revenue

    1,0041,014 Current liabilities of discontinued operations

    -2,663Total current liabilities

    6,3678,913Long Term Liabilities:Other long-term liabilities

    640810Total liabilities

    7,0079,723Stockholders' Equity:Convertible preferred stock

    55Common stock

    9492Additional paid-in capital

    38,95842,032Accumulated other comprehensive loss

    -(35)Treasury stock, at cost

    -(1,078)Accumulated deficit

    (17,152)(18,590)Total stockholders' equity

    21,90522,426Total liabilities and stockholders' equity

    $   28,912$   32,149 

    SOURCE IRIDEX Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. IRIDEX Announces Fourth Quarter and Full Year 2012
    2. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
    3. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
    4. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
    5. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
    6. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
    7. IRIDEX Reports 2012 Third Quarter Results
    8. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
    9. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
    10. IRIDEX Reports 2012 Second Quarter Results
    11. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
    Post Your Comments:
    (Date:12/1/2015)... DUBLIN , Dec. 01, 2015 /PRNewswire/ ... announced the addition of the "Medium ... Adhesives, Sealants, Lubricants, and Other Applications - ... and Forecast, 2015 - 2023" report ... ) has announced the addition of the ...
    (Date:12/1/2015)... 2015   Nottingham Spirk , a leading ... publication of a free whitepaper , "The ... The whitepaper gives medical product companies, pharmaceutical manufacturers ... lucrative segment. Nottingham Spirk survey ... their own health, save money (i.e., fewer doctors, ...
    (Date:12/1/2015)... Dec. 1, 2015 Array BioPharma ... that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The ... conference through a webcast on the Array ... , --> , ...
    Breaking Medicine Technology:
    (Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Center of Excellence (BHCOE) today announced that the organization has awarded Education and ... Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers that ...
    (Date:12/1/2015)... ... , ... McLean, VA., December 1, 2015 - Octo Consulting ... agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services Directorate. ... infrastructure, as well as operations and sustainment support to the NGA’s Agile Web ...
    (Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
    (Date:12/1/2015)... ... ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - Extreme ... 2016, the world’s largest Consumer Electronic Show, where they will present to a panel ... Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top names ...
    (Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
    Breaking Medicine News(10 mins):